Kate Newbold
凯特·纽博尔德
MBBS, FRCR, PhD
Consultant Clinical Oncologist; Head, Thyroid Cancer Unit咨询临床肿瘤医师；甲状腺癌病房主任
👥Biography 个人简介
Kate Newbold, MBBS, FRCR, PhD is a Consultant Clinical Oncologist at The Royal Marsden and head of the thyroid cancer program, specializing in radioiodine (RAI) therapy optimization, external beam radiotherapy, and targeted therapy for differentiated and anaplastic thyroid cancers. She has led clinical trials investigating strategies to restore RAI sensitivity in radioiodine-refractory DTC through redifferentiation with MAPK pathway inhibitors, including pivotal studies of selumetinib for redifferentiation. Her research addresses the biologic basis of RAI refractoriness and practical clinical approaches to restoring iodine uptake.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Selumetinib-Induced Redifferentiation in RAI-Refractory DTC
Led clinical evaluation of MEK inhibitor selumetinib to restore radioiodine uptake in patients with RAI-refractory DTC, demonstrating that MAPK pathway inhibition can re-sensitize dedifferentiated thyroid cancer to RAI therapy.
Thyroid Cancer Radiotherapy Dose-Fractionation Optimization
Investigated external beam radiotherapy regimens for locoregionally advanced thyroid cancer, contributing evidence for accelerated fractionation approaches in high-risk post-operative settings.
Multidisciplinary Thyroid Cancer Care Standards in the UK
Contributed to development of British Thyroid Association and NICE guidelines for differentiated and anaplastic thyroid cancer, standardizing evidence-based care across UK cancer centers.
Representative Works 代表性著作
Selumetinib-Enhanced Radioiodine Uptake in Advanced Thyroid Cancer
New England Journal of Medicine (2013)
Phase II study demonstrating that selumetinib increased radioiodine uptake and enabled therapeutic dosimetry in a proportion of patients with RAI-refractory DTC.
Radiotherapy in Differentiated Thyroid Cancer: Current Evidence and Future Directions
Clinical Oncology (2020)
Comprehensive review of external beam radiotherapy indications, techniques, and evidence in DTC management.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Hope S. Rugo
University of California, San Francisco (UCSF)
Maryam B. Lustberg
Yale School of Medicine / Yale Cancer Center
Sara M. Tolaney
Dana-Farber Cancer Institute / Harvard Medical School
Carlos H. Barrios
PUCRS (Pontifical Catholic University of Rio Grande do Sul) / Hospital São Lucas, Porto Alegre, Brazil
关注 凯特·纽博尔德 的研究动态
Follow Kate Newbold's research updates
留下邮箱，当我们发布与 Kate Newbold（The Royal Marsden NHS Foundation Trust）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment